Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B

Publication date: June 2018Source: Current Opinion in Virology, Volume 30Author(s): Aleksei Suslov, Stefan Wieland, Stephan MenneThe first line defense mechanisms against viral infection are mediated by the innate immune system. Viral components are detected by infected cells and/or innate immune cells that express different sensory receptors. They in turn mediate induction of direct antiviral mechanisms and further modulation of innate and adaptive immune responses. For evading the innate system, most viruses have evolved efficient mechanisms to block sensing and/or antiviral functions of the innate response. Interestingly, hepatitis B virus (HBV) seems to act like a stealth virus that escapes cell intrinsic antiviral mechanisms through avoiding recognition by the innate system rather than blocking its effector functions. In line with this concept, agonistic activation of innate immunity has emerged as a promising novel anti-HBV therapy approach with several compounds having advanced to the clinical stage.
Source: Current Opinion in Virology - Category: Virology Source Type: research